Sunday, September 24, 2017
 

 
 
DUBLIN, Sept. 22, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for Vraylar (cariprazine) for treatment of negative symptoms associated with schizophrenia in a.....   [READ MORE]
 
LONDON, September 22, 2017 /PRNewswire/ --   [READ MORE]
 
 
MORE NEWS
 
 
 
 
 
 
 
 
 
 
 
 
 
 





About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines